CN102408466B - New Salicomia europaea saponin and preparation method and applications thereof - Google Patents
New Salicomia europaea saponin and preparation method and applications thereof Download PDFInfo
- Publication number
- CN102408466B CN102408466B CN201110434057.9A CN201110434057A CN102408466B CN 102408466 B CN102408466 B CN 102408466B CN 201110434057 A CN201110434057 A CN 201110434057A CN 102408466 B CN102408466 B CN 102408466B
- Authority
- CN
- China
- Prior art keywords
- olean
- dihydroxy
- water
- 3beta
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229930182490 saponin Natural products 0.000 title claims abstract description 24
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 150000007949 saponins Chemical class 0.000 title description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- -1 oleanolic acid saponin compound Chemical class 0.000 claims abstract description 11
- 229940124599 anti-inflammatory drug Drugs 0.000 claims abstract description 7
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims abstract description 5
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims abstract description 5
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940100243 oleanolic acid Drugs 0.000 claims abstract description 5
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims abstract description 5
- WFBRNEFMHKPSKX-CBFMSKQISA-N 3beta,29-dihydroxy-olean-12-en-28-oic acid 28-O-beta-D-glucopyranosyl ester Natural products C[C@@]1(CO)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WFBRNEFMHKPSKX-CBFMSKQISA-N 0.000 claims description 44
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 241000201895 Salicornia Species 0.000 claims description 20
- 239000011347 resin Substances 0.000 claims description 11
- 229920005989 resin Polymers 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000004440 column chromatography Methods 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 238000001179 sorption measurement Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 239000006286 aqueous extract Substances 0.000 claims description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 2
- 239000008201 pharmaceutical excipient composition Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 5
- 102100037611 Lysophospholipase Human genes 0.000 abstract description 4
- 108010058864 Phospholipases A2 Proteins 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 235000017709 saponins Nutrition 0.000 description 21
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 230000004054 inflammatory process Effects 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 238000000605 extraction Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000000452 restraining effect Effects 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 206010014025 Ear swelling Diseases 0.000 description 4
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical compound CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 150000002475 indoles Chemical class 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000001896 rotating frame Overhauser effect spectroscopy Methods 0.000 description 4
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000013010 irrigating solution Substances 0.000 description 3
- 150000002617 leukotrienes Chemical class 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000011122 softwood Substances 0.000 description 3
- 201000004595 synovitis Diseases 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- 241000871189 Chenopodiaceae Species 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241001529246 Platymiscium Species 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 238000005100 correlation spectroscopy Methods 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 2
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000003358 phospholipase A2 inhibitor Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- YEBDWAHEIMUJQT-ZLCLUPBPSA-N (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O.CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YEBDWAHEIMUJQT-ZLCLUPBPSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101100068867 Caenorhabditis elegans glc-1 gene Proteins 0.000 description 1
- 101100068866 Caenorhabditis elegans glc-2 gene Proteins 0.000 description 1
- 125000003535 D-glucopyranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- QNCSIOQOWBORKW-UHFFFAOYSA-N O[C]=C Chemical group O[C]=C QNCSIOQOWBORKW-UHFFFAOYSA-N 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000015113 Salicornia europaea Species 0.000 description 1
- 235000003042 Salicornia europaea Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-UHFFFAOYSA-N alpha-D-glucopyranose Natural products OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002246 beta-d-glucopyranose Drugs 0.000 description 1
- 230000003570 biosynthesizing effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000002642 cobra venom Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 1
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical group CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the field of the natural pharmaceutical chemistry and discloses a chemical structure of a new oleanolic acid saponin compound which is extracted and separated from Salicomia europaea. The invention also discloses a preparation method of the compound and applications of the compound in the medical field, in particular applications of the compound in the field of inhibiting the activity of phospholipase A2 (PLA2) and preparing anti-inflammatory drugs.
Description
One, technical field:
The present invention relates to natural medicine field, be specifically related to extract the new saponin(e of one that separation obtains, its preparation method, and this saponin(e inhibition of phospholipase A from medicinal plant salicornia europaeal
2(PLA
2) active and in the purposes of preparing in anti-inflammatory drug.
Two, technical background:
Salicornia europaeal (Salicornia europaea Linn.) is Chenopodiaceae (Chenopodiaceae) salicornia europaeal platymiscium, mainly be distributed in saltings, seashore is taken up in salt lake, " China book on Chinese herbal medicine " records the effect of flat liver, diuresis, step-down, is among the peoplely commonly used to cure mainly hypertension and headache.In salicornia europaeal platymiscium, be rich in saponin component, its aglycon is mainly Oleanolic Acid aglycon.In the separation of the Chinese Academy of Sciences of Jiangsu Province medicinal plants study development centre saponin component in to salicornia europaeal, obtain a saponin compound, the clear and definite structure of this compound, pharmacologically active and purposes.
Phospholipase A2 (PLA
2) be present in various organisms. its physiological function is specificity hydrolytic phosphatide Sn-2 fat key, makes it to be decomposed into lipid acid and lysophospholipid.If lipid acid is arachidonic acid (arachidonic acid), be decomposed into respectively prostaglandin(PG) (prostaglandins) and leukotriene (leukotrienes) by cyclooxygenase (cyclooxygenase) and 5-lipoxygenase (lipoxygenase), prostaglandin(PG) is the precursor of inflammation, and leukotriene plays an important role in the pathogeny that causes asthma; The platelet activation factor (platelet-activating factor) that lysophospholipid is metabolized to is also the important medium that causes inflammation.PLA
2if in the biosynthetic key position of inflammation regulatory factor. can effectively suppress PLA
2activity, with the biosynthesizing of closely-related three regulatory factors of inflammatory process all by suppressed.Efficient single-minded PLA
2inhibitor likely develops into novel NSAID (non-steroidal anti-inflammatory drug).
Three, summary of the invention:
Technical problem
One of object of the present invention is to provide a kind of saponin compound (3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester) and preparation method thereof and this new compound is being prepared PLA
2the new purposes of inhibitor and anti-inflammatory drug.According to the present invention, this new compound can be prepared into medicine, for the preparation of PLA
2the treatment of the relative disease such as inhibitor and inflammation.
Technical scheme
The invention provides a kind of saponin compound and tool preparation method.This saponin compound that extraction in salicornia europaeal, separation, purifying obtain, called after 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester.
3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester, chemical name is: 3 β, 29-dihydroxyl volatile oil-12-alkene-28-carboxylic acid 28-O-β-D-Glucose ester,
Chemical structural formula is:
The preparation method of above-mentioned salicornia europaeal saponin compound, it is characterized in that: take the fresh herb of salicornia europaeal as raw material, through water or organic solvent or mixed solvent extraction, aqueous extract is directly crossed macroporous resin adsorption, after organic solvent or mixed solvent extracting solution are concentrated, be dissolved in water through macroporous resin adsorption or n-butanol extraction, macroporous resin adsorption thing or n-butyl alcohol extract obtain through column chromatography for separation again.Wherein, macroporous resin comprises D101, AB-5 or HP-20; Column chromatography is selected from one or more in silica gel, gel, aluminum oxide, polymeric amide, ODS and MCI with carrier; Organic solvent comprises methyl alcohol, ethanol or propyl carbinol; Extract temperature lower than 100 ℃.
The invention provides 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester and medically acceptable pharmaceutical excipient composition pharmaceutical composition and preparation thereof.As, tablet, pill, paste, capsule, oral liquid, granule and injection liquid powder injection or liquid drugs injection liquid.
The invention provides salicornia europaeal saponin compound and prepare PLA
2the application of inhibitor and anti-inflammatory drug.In vitro, the IC of 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester
50value and indoles PLA
2the IC of inhibitor
50close, in body, experiment shows 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester 20mgkg
-1and 40mgkg
-1two dosage groups can be passed through PLA
2active remarkable restraining effect, thereby the content of minimizing inflammatory mediator PGE, prompting 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester is similar to PLA
2the effect of inhibitor; In addition 40mgkg,
-1and 80mgkg
-1two dosage group p-Xylol induced mice ear swellings have obvious restraining effect.
Beneficial effect
The invention discloses the chemical structure of extracting a kind of oleanolic acid saponin class new compound separating from salicornia europaeal, and this compounds process for production thereof and the purposes in field of medicaments, especially preparing Phospholipase A2 (PLA
2) purposes of inhibitor and anti-inflammatory drug.In view of PLA
2the research of inhibitor can be research PLA
2mechanism in cell and molecular level complexity provides strong means, also open up wide treatment prospect for the treatment of clinical anti-inflammatory and various autoimmune disease, the present invention is of great practical significance for the saponins compound in abundant exploitation salicornia europaeal simultaneously.
Evidence, in vitro, the IC of 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester
50value and indoles PLA
2the IC of inhibitor
50close, in body, experiment shows 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester 20mgkg
-1and 40mgkg
-1two dosage groups can be passed through PLA
2active remarkable restraining effect, thereby the content of minimizing inflammatory mediator PGE, prompting 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester is similar to PLA
2the effect of inhibitor; In addition 40mgkg,
-1and 80mgkg
-1two dosage group p-Xylol induced mice ear swellings have obvious restraining effect, illustrate that 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester can be used for PLA
2the exploitation of inhibitor and anti-inflammatory drug.
Four, accompanying drawing explanation:
Can be used as annex material with figure below reports.
The ESI-MS spectrum of Fig. 1 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester
The HR-MS spectrum of Fig. 2 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester
Fig. 3 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester
1h-NMR spectrum
Fig. 4 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester
13c-NMR spectrum
The COSY spectrum of Fig. 5 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester
The HMQC spectrum of Fig. 6 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester
The HMBC spectrum of Fig. 7 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester
The ROESY spectrum of Fig. 8 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester
The extraction of Fig. 9 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester separates
The structural formula of Figure 10 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester
Five, embodiment:
In conjunction with embodiment, the invention will be further described, but content of the present invention is not restricted to cited embodiment.This saponins new compound that the present invention's extraction in salicornia europaeal, separation, purifying obtain, called after 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester.
1. extract and separate
Present inventor concentrates to obtain medicinal extract at this institute pilot plant with 90% alcohol reflux by salicornia europaeal herb, gets medicinal extract successively with sherwood oil, ethyl acetate extraction.Obtain sherwood oil portion, ethyl acetate portion and propyl carbinol portion.
Propyl carbinol portion adsorbs with macroporous resin, then with water-ethanol system segment wash-out, merges the component that contains saponin(e, obtains salicornia europaeal total saponins.Gained salicornia europaeal total saponins carries out silica gel column chromatography, and moving phase is followed successively by chloroform-methanol (10: 1,4: 1,2: 1,1: 1), methyl alcohol.Wherein chloroform-methanol (4: 1) part is through reversed-phase column separation and gel column purifying obtain monomeric compound 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester repeatedly.
2. Structural Identification
White amorphous powder, is soluble in methyl alcohol.The TLC vitriol oil-Vanillin displaing amaranth, after placing, color goes down.Molish reaction and Liebermann-Burchard reaction are all positive, and this compound of deducibility is triterpene saponin componds.
(c?0.11，MeOH)。The data that show according to Low Resolution Mass Spectra, m/z 673.30 ([M+K]
+), 657.30 ([M+Na]
+), 669.25 ([M+Cl]
-), 67930 ([M+HCOO]
-), 633.25 ([M-H]
-) show that its molecular weight is 634, in conjunction with
1the hydrogen signal of H-NMR and
13the carbon signal quantity of C-NMR, deduction molecular formula is C
36h
58o
9, degree of unsaturation is 8.This molecular formula is by high resolution mass spectrum (HR-ESI-MS), m/z 657.3991 ([M+Na]
+) (calculated value is 657.3979), further evidence.
1h-NMR (C
5d
5n, 500MHz, δ, ppm) 6 angular methyl(group) (δ 0.91,1.01 of demonstration, 1.08,1.13,1.20 and 1.25), an alkene hydrogen proton (δ 5.48,, and sugared anomeric proton signal (δ 6.33, d, J=8.1Hz) t-like).
13c-NMR (C
5d
5n, 125MHz, δ, ppm) show that the carbon signal of connection hydroxyl is δ
c78.1 (C-3-OH) and a hydroxy methylene are δ
c73.7, and this hydroxy methylene carbon signal shows and δ on hsqc spectrum
hthe unimodal of two hydrogen on 3.54 is correlated with.Relevant with H-23 (δ 1.20) according to H-H COSY and ROESY spectrum H-3 (δ 3.40), prove that the α position of the upper hydrogen proton of C-3 is orientated, therefore infer that 3 upper hydroxyls are β position orientation.Except E ring and sugared part, above
1h-NMR and
13the spectral data of C-NMR and Oleanolic Acid coincide.
In HMBC spectrogram, observe δ
hunimodal and the four carbon atom δ of two hydrogen of 3.54
c19.7,28.9 (C-21), 36.4 (C-20), 41.0 (C-19) intersects, and shows that C-29 or C-30 are oxidized.With the comparison of document nuclear magnetic data, infer C-29 (δ
c73.7) oxidized.
δ in ROESY spectrum
h1.08 and 3.32 (H-18, β-axial) intersects, and proves that 30 carbon are β positions, and therefore C-29 is positioned at α position.
13c-NMR shows δ 95.8 (Glc-1), 74.2 (Glc-2), 79.0 (Glc-3), 71.2 (Glc-4), 79.3 (Glc-5), 62.3 (Glc-6), may be Glucopyranose glycosyls.The monose that hydrolysis generates detects as Glucopyranose through TLC, infers that it is D-Glucopyranose again by its optical value, by the coupling constant J=8.1Hz of glucose terminal hydrogen, therefore infers and has connected β-D-Glucopyranose, the H (δ of sugared end group in HMBC spectrum
h6.33) and aglycon C-28 (δ
c176.5) relevant, show that glucose link position is triterpene aglycon C-28 position.
Comprehensive above analysis, new saponin(e structure is decided to be 3 β, 29-dihydroxyl volatile oil-12-alkene-28-carboxylic acid 28-O-β-D-Glucose ester.
The structure of the new saponin(e of Fig. 1 is relevant with ROESY with main HMBC (H → C)
Nuclear magnetic resonance data (δ, ppm, 0=TMS, the C of the new saponin(e of table 1
5d
5n)
New compound of the present invention can be made conventional pharmaceutical dosage form as active constituents of medicine, as, tablet, pill, paste, capsule, oral liquid, granule and injection liquid powder injection or liquid drugs injection liquid.
3. vitro inhibition PLA
2effect
Take SIBLINKS analogue as substrate, with Lp-PLA
2(the PLA extracting in cobra-venom
2) as lytic enzyme, indoles PLA
2inhibitor 5-methoxyl group-1-benzyl-1H-indole-3-acetamide is contrast, measures the maximum speed of reaction of hydrolysis by microplate reader colorimetric system, suppresses active qualitative, quantitative comparison, the results are shown in Table 2.
Table 2 is to PLA
2the predictor of restraining effect and SCORE
Show the IC of 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester from the result of table 2
50value and indoles PLA
2the IC of inhibitor
50close, measured value of experiment and SCORE predictor are corresponding relation, and prompting 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester is similar to PLA
2the effect of inhibitor.
4. anti-inflammatory action
(1) impact on Mice Auricle dimethylbenzene inflammation
To 60 random point 5 groups of male mices, 1. 2. 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester I (20mgkg of control group
-1), II (40mgkg
-1), III (80mgkg
-1) three 3. indomethacin group (8mgkg of dosage group
-1), each physiological saline of organizing gastric infusion or giving equivalent, every day 1 time, continuously 3d, 30min after last administration, the interior outside of every mouse auris dextra exterior feature is dripped and is coated with 20 μ l caused by dimethylbenzene xylene inflammation, and left ear in contrast, causes the de-cervical vertebra of scorching rear 30min and puts to death mouse, lay auricle respectively at left and right ear same area with diameter 7mm punch tool, weigh, with left and right auricle weight difference value representation swelling, the results are shown in Table 3.
The impact of table 3 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester p-Xylol induced mice auricle inflammation ear swelling degree (
n=15)
With model group comparison
*p < 0.05,
*p < 0.01
Experimental result shows, 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester 40mgkg
-1and 80mgkg
-1two dosage group p-Xylol induced mice ear swellings have obvious restraining effect, and prompting 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester has certain anti-inflammatory action.
(2) on Carrageenan is prepared the impact of rat Air-vesicle Synovitis inflammatory model
Get healthy SD male white rat, be divided at random 6 groups: 1. normal group; 2. model group; 3. 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester I (10mgkg
-1), II (20mgkg
-1), III (40mgkg
-1) three dosage; 4. Dexamethasone group (0.15mgkg
-1).Each treated animal ether is slightly anaesthetized, center, back s.c sterile air 20ml, and 3d supplements injection air 10ml and maintains air bag swelling, 6d gas intracapsular injection carrageenin 50mrkg
-1cause inflammation, Normal group is with method injecting normal saline isometric(al).Each treated animal in 3d start gastric infusion 1. 2. group give isometric(al) physiological saline, 6d cause scorching before 30min again administration be administered once.Cause animal i.p vetanarcol 25mgkg after scorching 6h
-1anesthesia, gas intracapsular injection is aseptic without calcium magnesium Hank ' s balanced salt solution (HBSS) 4ml lavation, collects irrigating solution, carries out the mensuration of leukocyte count and protein content in irrigating solution; Adopt Determining Micro Acid titration measuring PLA
2active; The content of exempting from method mensuration PGE is put in employing, the results are shown in Table 4.
Table 4 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester is to leukocyte count, protein and PGE content and PLA in rat Air-vesicle Synovitis irrigating solution
2active impact (
n=8)
With model group comparison
*p < 0.05,
*p < 0.01
On the basis of Mice Auricle inflammation test, carried out again rat Air-vesicle Synovitis disease test, result with tested last time basically identically, 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester can reduce leukocytic oozing out and the content of protein in perfusate; Meanwhile, 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester 20mgkg
-1and 40mgkg
-1two dosage groups can be passed through PLA
2active remarkable restraining effect, thereby the content of minimizing inflammatory mediator PGE, this experimental result and its vitro inhibition PLA
2effect is consistent, illustrates that 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester can be used for PLA
2the exploitation of inhibitor and anti-medicament for the eyes thing.
In conjunction with embodiment, the invention will be further described, but content of the present invention is not restricted to cited embodiment.
The fresh herb 50Kg of salicornia europaeal, with 90% alcohol reflux three times, 200 liters of consumptions, each 3 days, the concentrated concentrated solution being merged into without alcohol taste, obtained total medicinal extract.Use successively again sherwood oil, ethyl acetate, n-butanol extraction.N-butyl alcohol extract obtains respectively 1 gram of 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester after column chromatography for separation.(seeing accompanying drawing 9)
Salicornia europaeal herb 10Kg, water heating is extracted three times, water consumption is 20 liters, extraction time is 1 hour, extracting temperature is 70 ℃, and extracting solution is through macroporous resin (D101, AB-5, HP-20 etc.) absorption, water, after 30% alcohol flushing, use 70% ethanol elution, 70% ethanol eluate decompression and solvent recovery obtains saponin(e mixture.Mixture after column chromatography (silica gel column chromatography: chloroform-methanol system, RP-C18 column chromatography: water-methanol system) separates, obtains respectively 0.2 gram of 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester again.
Salicornia europaeal herb 10Kg, with methyl alcohol cold soaking extraction three times, methanol usage is 20 liters, and extraction time is 1 day, and extracting solution adsorbs through macroporous resin (D101, AB-5, HP-20 etc.).Water, uses 70% ethanol elution after 30% alcohol flushing, 70% ethanol eluate decompression and solvent recovery obtains saponin(e mixture.Mixture after column chromatography (silica gel column chromatography: chloroform-methanol system, RP-C18 column chromatography: water-methanol system) separates, obtains respectively 0.25 gram of 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester again.
Get 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester compound 100mg and starch 50mg that embodiment 1 makes, dextrin 50mg mixes, and makees wetting agent with appropriate 30% ethanol, makes softwood, and ordinary method is granulated, and adds appropriate Magnesium Stearate mixing, makes tablet.
Get 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester compound 50mg and starch 70mg, dextrin 10mg, Icing Sugar 10mg mixes, and makees wetting agent with appropriate 30% ethanol, makes softwood, and ordinary method granulation, packs in hard capsule.
Get 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester compound 80mg and Vltra tears K15M 120mg, ethyl cellulose 45cps40mg, lactose 40mg mixes, appropriate with 10% V-Pyrol RC k30 ethanolic soln, make softwood, ordinary method is granulated, and packs into and in hard capsule, makes slow releasing capsule.
Claims (6)
1. an oleanolic acid saponin compounds 3BETA,29-dihydroxy-olean-12-en-28-oic acid 28-O-BETA-D-glucopyranosyl ester, is characterized in that chemistry 3 β by name, 29-dihydroxy-olean-12-en-28-oic acid28-O-β-D-glucopyranosyl ester, and chemical structural formula is:
2. the method for preparing compound described in claim 1, is characterized in that take salicornia europaeal as raw material, extracts through the mixing solutions of water, methyl alcohol, ethanol or methanol-water, alcohol-water; Aqueous extract is directly crossed macroporous resin adsorption, and macroporous resin adsorption was dissolved in water after the extracting solution of the mixing solutions of methyl alcohol, ethanol or methanol-water, alcohol-water is concentrated; Macroporous resin adsorption thing obtains through column chromatography for separation.
3. preparation method according to claim 2, is characterized in that described macroporous resin is the one in D101, AB-8, HP-20; Column chromatography is selected from one or more in silica gel, gel, aluminum oxide, polymeric amide, ODS and MCI with carrier.
4. the pharmaceutical preparation of compound claimed in claim 1 and medically acceptable pharmaceutical excipient composition.
5. preparation according to claim 4, is characterized in that formulation is tablet, capsule and injection.
6. compound claimed in claim 1 is in the purposes of preparing in anti-inflammatory drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110434057.9A CN102408466B (en) | 2011-12-22 | 2011-12-22 | New Salicomia europaea saponin and preparation method and applications thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110434057.9A CN102408466B (en) | 2011-12-22 | 2011-12-22 | New Salicomia europaea saponin and preparation method and applications thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102408466A CN102408466A (en) | 2012-04-11 |
| CN102408466B true CN102408466B (en) | 2014-05-14 |
Family
ID=45910851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110434057.9A Expired - Fee Related CN102408466B (en) | 2011-12-22 | 2011-12-22 | New Salicomia europaea saponin and preparation method and applications thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102408466B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103768078B (en) * | 2012-10-22 | 2019-02-05 | 北京大学 | Tetraterpene derivatives and its anti influenza purposes |
| CN106420772B (en) * | 2016-09-13 | 2017-07-28 | 武汉钧安制药有限公司 | A kind of pharmaceutical composition for treating acute pancreatitis |
| CN114276404B (en) * | 2021-12-24 | 2023-07-25 | 五邑大学 | Glycyrrhetinic acid glycerophospholipid compound, secretory phospholipase A2 sensitive liposome and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101074259B (en) * | 2007-03-08 | 2010-04-21 | 江苏省中国科学院植物研究所 | Saponin compound, its production and use |
-
2011
- 2011-12-22 CN CN201110434057.9A patent/CN102408466B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102408466A (en) | 2012-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101279964B (en) | Guaiane type sesquiterpenes, preparation and medical use thereof | |
| CN101074259B (en) | Saponin compound, its production and use | |
| CN101775061A (en) | Ilex latifolia thunb saponin compound | |
| CN100584856C (en) | The purposes of a kind of Hederagenin, its preparation method and preparation antitumor drug thereof | |
| CN105232891B (en) | The preparation method of trilliaceae extract and wherein saponins compound and its preparing the application in anti-ischemic heart medicine | |
| CN102408466B (en) | New Salicomia europaea saponin and preparation method and applications thereof | |
| CN102408464B (en) | Triterpene saponins compound and its production and use falls in one | |
| CN106008485A (en) | Medicinal composition of glimepiride, and application thereof in biomedicines | |
| CN106008543A (en) | Novel diterpenoid compound and preparation method thereof | |
| CN101307090B (en) | Method for preparing timosaponin BIII and uses thereof | |
| CN106619652A (en) | Preparation method of spermacoce latifolia triterpenoids and application of spermacoce latifolia triterpenoids in preparation of glycosidase inhibitor drug | |
| CN101416970A (en) | Use of arjunolic acid in preparing glycosidase inhibitor | |
| CN105820053A (en) | Pharmaceutical composition of cefalexin and application of pharmaceutical composition in biological medicine | |
| CN103232518B (en) | Triterpene saponins compound and its production and use falls in a kind of new Salicornia Bigelovii Torr. | |
| Sethiya et al. | Phytopharmacologic aspects of Canscora decussata Roem and Schult | |
| CN101628855A (en) | Laurane type sesquiterpene compound or derivative thereof and preparation method and application thereof | |
| CN104083348B (en) | Four kinds of kauran diterpene compounds are preparing the application in glycosidase inhibitor | |
| CN103638031B (en) | The preparation method of compound quinatic acid and the application in preparing glycosidase inhibitor | |
| CN104383547B (en) | Herba Saussureae Involueratae extract phosphatide complexes, oral disnitegration tablet and preparation method thereof | |
| CN105801590A (en) | Alprazolam pharmaceutical composition and anti-inflammatory and analgesic effects thereof | |
| CN102050862B (en) | New honeysuckle chlorogenic acid ester saponin as well as preparation method and use thereof | |
| CN104910237B (en) | Methyl reduced oleanane triterpenoid saponin, preparation method of its active composition and application thereof | |
| CN105884841B (en) | A kind of preparation method of phenylpropanoids | |
| CN101838296B (en) | Preparation method and application of new poly-alkyne-glycoside | |
| CN100509831C (en) | Wheat bran flavonoid compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140514 Termination date: 20161222 |